EntroGen Launches Multiplexed Leukemia Translocation Panel

Share Article

EntroGen's Leukemia Translocation Panel is a multiplexed, one-step RT-PCR assay that detects eleven variants in 6 common leukemia-associated translocations simultaneously.

Today EntroGen (http://www.entrogen.com) announced immediate availability of its new Leukemia Translocation Panel—a multiplexed, one-step RT-PCR assay that detects eleven variants in 6 common leukemia-associated translocations simultaneously.

EntroGen’s Leukemia Translocation Panel provides an efficient and rapid solution for the detection and identification of AML1-ETO, CBFB-MYH11, MLL-AF4, TEL-AML1, E2A-PBX1, and PML-RARA fusion gene transcripts from total RNA isolated from blood or bone marrow during initial diagnosis. The assay is compatible with several leading multi-channel real-time PCR instruments capable of detecting four commonly used fluorescent probes and produces results in just 90 minutes.

EntroGen also offers separate one-step, RT-PCR kits for detecting BCR-ABL fusion gene translocations p190 and p210. These kits may be run together with the Leukemia Translocation Panel for a comprehensive test for fusion genes implicated in CML, ALL, APL, and AML. Following initial diagnosis, EntroGen offers separate quantitative kits specific to each individual fusion gene transcript for monitoring residual disease.

The Leukemia Translocation Panel and individual fusion gene detection kits come with data analysis software to automate reporting. BCR-ABL p210 also includes WHO standards that enable reporting on the International Scale (IS).

The company is obtaining a CE-IVD marking in the EU for the Leukemia Translocation Panel. The individual fusion gene detection kits, including BCR-ABL p190 and p210, are CE-IVD marked. All products are available in the USA for research use.

About EntroGen

Based in Los Angeles, California, EntroGen (http://www.entrogen.com) is a biotechnology company with a focus on molecular diagnostic products in the areas of hematology and oncology. EntroGen has a growing commercial portfolio with many of its products being used to guide and monitor targeted therapies for various malignancies. EntroGen’s footprint reaches every corner of the globe delivering reliable clinical and research products.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Sales
EntroGen, Inc.
+1 (818) 716-1070 Ext: 111
Email >
@EntroGen
Follow >
Visit website